IQVIA Holdings Inc. (VIE:IQVH)
Austria · Delayed Price · Currency is EUR | Market Cap | 23.27B -7.1% |
| Revenue (ttm) | 13.89B +5.9% |
| Net Income | 1.16B -0.9% |
| EPS | 6.68 +4.7% |
| Shares Out | n/a |
| PE Ratio | 20.09 |
| Forward PE | 12.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 4 |
| Open | 137.55 |
| Previous Close | 137.50 |
| Day's Range | 137.40 - 138.40 |
| 52-Week Range | 120.00 - 209.70 |
| Beta | n/a |
| RSI | 38.22 |
| Earnings Date | May 5, 2026 |
About IQVIA Holdings
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial numbers in USD Financial StatementsNews
IQVIA to Announce First-Quarter 2026 Results on May 5, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced...
IQVIA Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
AI is driving revenue and margin growth, with over 150 agents deployed and plans for 500+ by 2027. Demand is strong, especially in biotech, which is expanding into clinical and commercial stages. Recent acquisitions enhance drug discovery capabilities, while productivity programs and automation support margin expansion.
IQVIA Holdings Transcript: Leerink Global Healthcare Conference 2026
AI is driving efficiency and new revenue streams, supported by proprietary data and advanced agent deployment. Market stability has returned post-COVID, with biotech and large pharma fueling growth. The Cedar Gate acquisition enhances US patient analytics and real-world evidence capabilities.
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Releases its 2025 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sci...
IQVIA Holdings Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day
Strong Q4 growth and stable margins were reported, with Commercial Solutions and R&DS segments showing momentum. AI is seen as a major opportunity, leveraging proprietary data and new agentic solutions, while only minor consulting areas face risk. Leadership transition emphasizes continuity and optimism for future growth.
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the li...
IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA forecasts weak annual profit on higher interest expenses
Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re...
IQVIA Holdings Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year 2025 results with 6% revenue growth and robust free cash flow. 2026 guidance projects continued growth, supported by AI-driven solutions, strategic acquisitions, and strong demand across segments.
IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its catego...
IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and heal...
IQVIA Holdings Transcript: UBS Global Healthcare Conference 2025
Q3 results were strong, with bookings and RFPs signaling improving demand as industry uncertainty recedes. Pricing and margins have stabilized, and long-term growth targets remain intact, supported by operational efficiencies and AI initiatives.
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of ...
IQVIA Holdings Earnings Call Transcript: Q3 2025
Q3 saw strong revenue and record free cash flow, with robust bookings and backlog growth. Guidance for 2025 was reaffirmed, with all segments performing well and AI initiatives expanding to drive future efficiency and margin improvement.
IQVIA narrows annual profit forecast amid continued research contract cancellations
IQVIA Holdings on Tuesday narrowed its annual profit forecast, trimming the upper end of its outlook, as it expects cancellations of research contracts from pharmaceutical clients to persist into the ...
IQVIA Reports Third-Quarter 2025 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...